-
52-week Open Label Safety-Tolerability Study
NCT07369154 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville, Little Rock
-
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Little Rock, Rogers
-
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Arkansas: Bryant
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville, Little Rock, Rogers
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Arkansas: Bryant
-
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bryant, Little Rock
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bryant, Little Rock
-
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Rogers
-
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville, Little Rock, Rogers
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville, Little Rock, Rogers
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591 ·
Phase: Phase 4 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville
-
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Arkansas: Bentonville, Little Rock
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Arkansas: Little Rock
-
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
NCT07680946 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Arkansas: Little Rock